Once-daily ceftriaxone in the treatment of lower respiratory tract infections.
We conducted a retrospective clinical evaluation to assess the efficacy of a 1-gram once-daily regimen of intravenously administered ceftriaxone in the treatment of a variety of bacterial infections. Of the 250 patients studied, 167 had infections of the lower respiratory tract, approximately 70% of which were diagnosed as community-acquired pneumonias. The principal identified pathogens were Staphylococcus aureus and Haemophilus influenzae. Forty per cent of community-acquired pneumonias occurred in patients over 69 years of age, who showed a 13% mortality compared to a mortality rate of 4% in younger patients. Once-daily ceftriaxone was effective and well tolerated as empiric therapy for pneumonia likely to be caused by susceptible organisms.
Brown
R
R
Infectious Disease Division, Baystate Medical Center, Boston, Mass.
D000368:Aged; D001991:Bronchitis / Q000188:drug therapy*; D002443:Ceftriaxone / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy; D006193:Haemophilus influenzae; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011014:Pneumonia / Q000188:drug therapy*; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy; D012189:Retrospective Studies
D002443:Ceftriaxone